Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.55 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33268 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL1736809 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL29572486 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL12837999 | 1.00 | CREBBP (0.55) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL10670441 | 0.81 | CREBBP (0.57) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL4130897 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL14946402 | 0.78 | GAA (0.47) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL29641564 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL19230496 | 0.78 | BRD4 (0.46) | CREBBPBRD4TSHREP300GAA | |
| SCHEMBL424121 | 0.78 | MTNR1A (0.45) | CREBBPBRD4TSHREP300GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435941-B2 | Mini-hepcidin peptides and methods of using thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-07 | — | — | US | claimed |
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20120263848-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2012-10-18 | — | — | US | disclosed |
| EP-2493853-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051394-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-7323575-B2 | Process for the synthesis of (2S)-indoline-2-carboxylic acid | LES LABORATORIES SERVIER (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20070112204-A1 | Process for the synthesis of (2S)-indoline-2-carboxylic acid | LES LABORATOIRES SERVIER (FR) | 2007-05-17 | — | — | US | disclosed |
| US-7196204-B2 | Method for the synthesis of s-indoline-2-carboxylic acid and application thereof in the synthesis of perindopril | LES LABORATOIRES SERVIER (FR) | 2007-03-27 | — | — | US | disclosed |
| US-7087597-B1 | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1223170-B1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1223170-A1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CREBBP 1545/4885BRD4 57/4885TSHR 707/4885 |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | OR51E2, OR10J3, ORC3 | CREBBP 1097/4885BRD4 2437/4885TSHR 1036/4885 |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | CREBBP 1699/4885BRD4 2651/4885TSHR 4454/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | CREBBP 4440/4885BRD4 472/4885TSHR 1793/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CREBBP 2136/4885BRD4 611/4885TSHR 4501/4885 |
| US-20120263848-A1 | Organic Compounds | OR10J3, CBR3, C9 | CREBBP 1341/4885BRD4 399/4885TSHR 1171/4885 |
| US-20070112204-A1 | Process for the synthesis of (2S)-indoline-2-carboxylic acid | IMPDH2, PDK4, QDPR | CREBBP 2569/4885BRD4 2821/4885TSHR 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.